ReviewJournal of clinical medicine2025
Platelet-Rich Plasma for Knee Osteoarthritis: A Comprehensive Narrative Review of the Mechanisms, Preparation Protocols, and Clinical Evidence.
Review in Journal of clinical medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Academic Influence and Industry Funding in Platelet-Rich Plasma Injections: Coauthorship Network Analysis.Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews · 2026Pooled it
- Intra-articular platelet-rich plasma demonstrates superior clinical and serum biomarker outcomes compared with corticosteroids and NSAIDs in late-stage knee osteoarthritis: a randomised controlled trial.Journal of orthopaedic surgery and research · 2026Trial
- Cryopreserved umbilical allograft (equicenta® CTM) improves clinical outcomes compared with clinician-selected standard of care in performance horses: a pragmatic prospective controlled trial.Frontiers in veterinary science · 2026Trial
- Availability and Pricing of Orthobiologic Knee Injections Vary by Practice Type but Not by Community Socioeconomic Vulnerability in Suburban New York.Arthroscopy, sports medicine, and rehabilitation · 2026Article
- Biomimetic cellular sponges for neutralizing inflammatory cytokines in osteoarthritic joints.Materials today. Bio · 2026Article
- Outcome Analysis of Leukocyte-Rich Platelet-Rich Plasma, Leukocyte-Poor Platelet-Rich Plasma, and Injectable Platelet-Rich Fibrin in the Management of Chronic Plantar Fasciitis: A Prospective Comparative Study.Journal of orthopaedic case reports · 2026Article
- Platelet-Rich Plasma in Chronic Joint Pain: An Autologous Alternative to Steroids.Current pain and headache reports · 2026Review
- Cord Blood-Derived Versus Homologous Donor Platelet-Rich Plasma (PRP) in Early Knee Osteoarthritis: A Single-Center, Randomized, Double-Blind Pilot Clinical Trial.Bioengineering (Basel, Switzerland) · 2026Article
- Temporal Hierarchy of Hydrogels and Orthobiologic Therapies for Knee Osteoarthritis.Gels (Basel, Switzerland) · 2026Review
- Short-Term Clinical Outcomes and Systemic Inflammatory Biomarker Responses Following Platelet-Rich Plasma Injection in Knee Osteoarthritis.Life (Basel, Switzerland) · 2026Article
- Efficacy and Safety of a Defined Two-Dose Protocol of Autologous Platelet-Rich Plasma (PRP) Injection for Refractory Chronic Non-Healing Wounds: A Prospective Clinical Study.International wound journal · 2026Article
- Nutritional Interventions to Optimize Orthobiologic Therapy Quality in Type 2 Diabetes Mellitus: Molecular Mechanisms and Clinical Framework: A Narrative Review.International journal of molecular sciences · 2026Review
- Influence of platelet-rich plasma composition on pain and functional performance in knee osteoarthritis: a systematic review and network meta-analysis.Knee surgery & related research · 2026Review
- Efficacy and Safety of Platelet-Rich Plasma in Knee Osteoarthritis: Umbrella Meta-Analysis Based on Clinical Evidence, Methodological Quality and Therapeutic Positioning.Clinics and practice · 2026Review
- Biologic and regenerative strategies for osteoarthritis: advances in MSC, exosome, and PRP based therapies.Frontiers in pharmacology · 2026Review
- Effects of platelet-rich plasma-assisted arthroscopic debridement plus microfracture surgery on visual analogue scale scores and cartilage repair indicators in early-stage knee osteoarthritis.American journal of translational research · 2026Article
- Interventional Pain Procedures: A Narrative Review Focusing on Safety and Complications. Part 4 - Peripheral Nerve, Joint, Musculoskeletal, and Regenerative Interventions.Journal of pain research · 2026Review
- Platelet-rich plasma for treatment of knee osteoarthritis: a narrative review.Frontiers in pain research (Lausanne, Switzerland) · 2026Review
- Immune heterogeneity-driven therapeutic responses to platelet-rich plasma and TRPV1 antagonism in osteoarthritis.Frontiers in pharmacology · 2026Article
- Mechanistic insights into gut microbiota dysbiosis in osteoarthritis based on the gut-joint axis.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPlatelet-rich plasma (PRP) is increasingly utilized for managing knee osteoarthritis (KOA), yet its clinical value remains debated due to the variability in preparation protocols and outcome measures.
methodsThis narrative review synthesizes current evidence from 40 high-quality studies published between 2013 and March 2025, including randomized controlled trials, systematic reviews, and meta-analyses. The biological mechanisms, clinical effectiveness, safety, and implementation challenges of PRP therapy in KOA are examined.
resultsPRP injections-particularly leukocyte-poor PRP-demonstrate superior pain relief and functional improvement compared to hyaluronic acid and corticosteroids, especially in patients with mild to moderate KOA (Kellgren-Lawrence grades I-III). However, heterogeneity in PRP formulations (platelet/leukocyte content and activation protocols), injection regimens, and follow-up durations limits direct comparability across studies. Evidence from high-quality placebo-controlled trials shows inconsistent long-term benefits, with some failing to demonstrate superiority over saline beyond 6-12 months. The GRADE assessment rates the overall certainty of evidence as moderate. PRP appears safe, with few adverse events reported, but remains costly and variably reimbursed. Guidelines from major societies remain cautious or inconclusive.
conclusionsPRP is a promising, safe, and well-tolerated option for early to moderate KOA. However, the standardization of preparation protocols, patient selection criteria, and outcome reporting is essential to improve comparability and guide clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.